Acacia Pharma Gets FDA Approval for Post Op Therapeutics
PONV affects 30% of all surgical patients
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowUnited Kingdom-based Acacia Pharma Group plc, which has research facilities in Indianapolis, has announced the U.S. Food and Drug Administration has approved BARHEMSYS, an injectable drug for the prevention and treatment of postoperative nausea and vomiting.
PONV is common in patients following significant treatments or invasive procedures, including surgery or cancer chemotherapy. Acacia says it occurs in 30% of all surgical patients.
“The approval of our first product represents a significant milestone in Acacia Pharma’s evolution into an integrated hospital pharmaceutical company with strong development and commercialization capabilities,” said Mike Bolinder, Acacia Pharma’s chief executive officer.
T.J. Gan, the chairman of the Department of Anesthesiology at Stony Brook University in New York, said PONV is a major problem and there have been few medical advances to improve post-op for patients.
“It is often considered by patients to be the most undesirable complication of surgery, even worse than pain,” said Gan.
“Our goal is for BARHEMSYS to become established as the new standard of care in the US for the treatment of PONV in patients who have failed standard prophylaxis,” said Bolinder.
The company says it plans to launch BARHEMSYS in the second half of 2020.
Inside INdiana Business reporter Kylie Veleta in April 2019 profiled Acacia Pharma, what was then an up-and-coming young pharma protege. Click here to read the story.